Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease.

BACKGROUND AND OBJECTIVES Serum alkaline phosphatase has been associated with increased mortality in hemodialysis patients but its associations with mortality in chronic kidney disease (CKD) stages III and IV are unknown. Design, settings, participants & measurements: In 1094 participants in the African-American Study of Kidney Disease and Hypertension (AASK) database, the associations of serum alkaline phosphatase with mortality and cardiovascular events were examined in Cox models. RESULTS The mean (+/-SD) age was 54 +/- 11 yr, and 61% were men. The median alkaline phosphatase was 80 IU/L, and interquartile range was 66 to 97 IU/L. The mean follow-up was 4.6 yr. There were 105 (9.6%) all-cause deaths and 149 (13.6%) cardiovascular events. Each doubling of serum alkaline phosphatase was significantly associated with increased hazard [hazard ratio (HR) 1.60, 95% confidence interval (CI) 1.08 -2.36] of all-cause mortality adjusted for demographics, drug and blood pressure groups, and comorbidity. With further adjustment for liver function tests as well as serum calcium and phosphorus, each doubling of serum alkaline phosphatase remained significantly associated with increased mortality (HR 1.55, 95% CI 1.03 to 2.33). Serum alkaline phosphatase was not significantly associated with increased risk of cardiovascular events. CONCLUSIONS Independent of liver function tests and serum calcium and phosphorus, higher levels of serum alkaline phosphatase are associated with increased mortality in the CKD population. Further studies are warranted to identify the potential mechanisms for this association.

[1]  F. Port,et al.  Response to ‘About the association between high alkaline phosphatase and risk of death and hospitalization in dialysis patients’ , 2009 .

[2]  Hwai-Jeng Lin,et al.  Factors aside from Helicobacter pylori play an important role in the occurrence of peptic ulcer in dialysis patients. , 2009, Kidney international.

[3]  S. Browning,et al.  Bone Markers Predict Cardiovascular Events in Chronic Kidney Disease , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  C. Chazot,et al.  Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  J. Bragg-Gresham,et al.  High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. , 2008, Kidney international.

[6]  J. Millán,et al.  Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. , 2008, Kidney international.

[7]  C. Lau,et al.  Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese , 2008, Clinical chemistry and laboratory medicine.

[8]  M. Taal,et al.  Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[9]  J. Millán,et al.  Novel Inhibitors of Alkaline Phosphatase Suppress Vascular Smooth Muscle Cell Calcification , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  A. Avogaro,et al.  The good and the bad in the link between insulin resistance and vascular calcification. , 2007, Atherosclerosis.

[11]  Grace H. Lee,et al.  Impact of kidney bone disease and its management on survival of patients on dialysis. , 2007, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[12]  M. Budoff,et al.  Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. , 2006, Kidney international.

[13]  S. Haffner,et al.  Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. , 2005, Diabetes.

[14]  W. Markiewicz,et al.  Association Between Elevated Liver Enzymes and C-Reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[16]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.